Treatment of old world cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination

International Journal of Dermatology

Volumn 48, Issue 8, 2009, Pages 862-869

  Al mutairi, Nawaf ^a,b   Alshiltawy, Mazen ^a   Khalawany, Mohamed El ^a   Joshi, Arun ^a   Eassa, Bayoumy Ibrahim ^a   Manchanda, Yashpal ^a   Gomaa, Samir ^a   Darwish, Ibrahim ^a   Rijhwani, Manish ^a  

^a FARWANIYA HOSPITAL   (Kuwait)

^b NONE   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; IMIQUIMOD; ITRACONAZOLE; AMINOQUINOLINE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CRYOTHERAPY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEISHMANIA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARASITOLOGY; SKIN BIOPSY; SKIN LEISHMANIASIS; DRUG COMBINATION; KUWAIT; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTPATIENT DEPARTMENT; PATHOLOGY; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; AMINOQUINOLINES; ANTI-INFECTIVE AGENTS; ANTIPROTOZOAL AGENTS; COMBINED MODALITY THERAPY; CRYOTHERAPY; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITRACONAZOLE; KUWAIT; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67949109744     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.04010.x     Document Type: Article

References (42)

1. Lewis D. Phlebotomid sandfly. Bull WHO 1971; 14: 535.
2. World Health Organization (WHO). Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990; 793: 1-158.
3. Antinori S, Gianelli E, Calattini S, et al. Cutaneous leishmaniasis: An increasing threat for travellers. Clin Microbiol Infect 2005; 11: 343-346.
4. Mahajan VK, Sharma NL. Therapeutic options for cutaneous leishmaniasis. J Dermatol Treat 2007; 18: 97-104.
5. World Health Organization (WHO). Leishmaniasis. In: Thirteenth Programme Report. Special Programme for Research and Training in Tropical Diseases (TDR). Geneva: WHO Publications, 1997: 100-111.
6. World Health Organization (WHO). The Leishmaniases. Technical Report Series 701. Geneva: WHO, 1984: 1-140.
7. Walton BC. Leishmaniasis. A worldwide problem. Int J Dermatol 1989; 28: 305-307.
8. Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet 2005; 366: 1561-1577.
9. Croft AM, Lestringant GG, Baker BC. Cutaneous leishmaniasis following military deployment to Iraq. Med Trop (Mars) 2006; 66: 185-188.
10. Al-Shammari SA, Khoja TA, Fehr A. Cutaneous leishmaniasis in Riyadh region: Four-year study of the epidemiologic and clinical features. Int J Dermatol 1992; 31: 565-567.
11. Uthman MA, Satir AA, Tabbara KS. Clinical and histopathological features of zoonotic cutaneous leishmaniasis in Saudi Arabia. J Eur Acad Dermatol Venereol 2005; 19: 431-436.
12. Ul Bari A, Ber Rahman S. Correlation of clinical, histopathological, and microbiological findings in 60 cases of cutaneous leishmaniasis. Indian J Dermatol Venereol Leprol 2006; 72: 28-32.
13. Walsh DS, Balagon MV, Abalos RM, et al. Multiple lesions of sporotrichoid leishmaniasis in a Filipino expatriate. J Am Acad Dermatol 1997; 36: 847-849.
14. Weigle KA, de Davalos M, Heredia P, et al. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Columbia: A comparison of seven methods. Am J Trop Med Hyg 1987; 36: 489-496.
15. Andresen K, Gaafar A, El-Hassan AM, et al. Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: A comparison with direct microscopy of smears and section from lesions. Trans R Soc Trop Med Hyg 1996; 90: 133-139.
16. Belli A, Rodriguez B, Aviles H, et al. Simplified PCR detection of New World leishmania in clinical specimens of cutaneous leishmaniasis. Am J Trop Med Hyg 1998; 58: 102-109.
17. Berman JD. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10.years. Clin Infect Dis 1997; 24: 684-703.
18. Singh S, Kumar J, Singh R, et al. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable antileishmanial drugs: A community based study. Int J Infect Dis 2004; 4: 203-208.
19. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (pentosam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296-306.
20. Grogl M, Thomson TN, Franke ED. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg 1992; 47: 117-126.
21. Bassiouny A, El Meshad M, Talaat M et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982; 107: 467-474.
22. Panagiotopoulos A, Stavropoulos PG, Hasapi V, et al. Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol 2005; 44: 749-752.
23. Al Gindan Y, Kubba R, Omer A, et al. Cryosurgery in Old World cutaneous leishmaniasis. Br J Dermatol 1988; 118: 851-854.
24. Darouti M, Rabbi S. Cutaneous leishmaniasis: Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990; 29: 56-59.
25. Uzun S, Uslular C, Yucel A, et al. Cutaneous leishmaniasis, evaluation of 3074 cases in the Curkurova region of Turkey. Br J Dermatol 1999; 140: 347-350.
26. Salmanpour R, Reza RM, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006; 45: 1115-1116.
27. Hart DT, Lauwers WJ, Willemsens G, et al. Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. Mol Biochem Parasitol 1989; 33: 123-134.
28. Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intralesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatol Treat 2001; 12: 159-162.
29. Al-Fouzan AS, Al Saleh QA, Najem NM, et al. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol 1991; 30: 519-521.
30. Momeni AZ, Aminjawaheri M, Omidghaemi MR. Treatment of CL with ketoconazole cream. J Dermatol Treat 2003; 14: 26-29.
31. Dogra J, Saxena VN. Itraconazole and leishmaniasis: A randomised double-blind trial in cutaneous disease. Int J Parasitol 1996; 26: 1413-1415.
32. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005; 19: 80-83.
33. Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol 1996; 132: 784-786.
34. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85: 212-213.
35. Dogra J, Lal BB, Misra SN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986; 25: 398-400.
36. Elena OL, Ricardo P, Elena MC, et al. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 1998; 351: 498-499.
37. Arevealo I, Ward BJ, Miller R, et al. Successful treatment of drug resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33: 1847-1851.
38. Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, et al. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005; 40: 1395-1403.
39. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007; 44: 1549-1554.
40. Berman B, Villa A. Imiquimod 5% cream for keloid management. Dermatol Surg 2003; 47: S209-S211.
41. Crawford R, Holmes D, Meymandi S. Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intralesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis. J Am Acad Dermatol 2005; 52 (Suppl. 1): S 118.
42. Seeberger J, Daoud S, Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol 2003; 42: 576-579.